Literature DB >> 16954441

Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour.

N Garcia de la Torre1, I Buley, J A H Wass, H E Turner.   

Abstract

The role of angiogenesis and lymphangiogenesis in thyroid cancer pathogenesis has not been elucidated. Patterns for tumour behaviour and metastasic spread vary according to tumour type and whether differences in the angiogenic or lymphangiogenic phenotype influence the route for tumour metastases or determine a more aggressive behaviour has not been fully explored. The angiogenic and lymphangiogenic phenotypes of a large cohort of thyroid proliferative lesions (n=191) were studied. Using immunohistochemistry for CD34, lymphatic vessel endothelial receptor-1 (LYVE-1) (specific markers for vascular and lymphatic endothelium respectively), vascular endothelial growth factor (VEGF-A), VEGF-C and fibroblast growth factor-2 (FGF-2), this study analyses microvascular density (MVD), lymphatic vascular density (LVD), and expression of angiogenic and lymphangiogenic factors in normal thyroid (NT; n=19), multinodular goitre (n=25), toxic multinodular goitre (n=8), Graves' hyperplasia (n=22), follicular adenoma (n=54), papillary carcinoma (PC; n=27), incidental papillary microcarcinoma (PMC; n=8), follicular carcinoma (FC; n=20) and medullary carcinoma (MC; n=8). MVD was decreased in proliferative lesions, benign and malignant, compared with NT (P<0.0001). In contrast, VEGF-A expression was increased in thyroid carcinomas (PC, FC and MC) when compared with PMC, benign lesions and NT (P<0.0001). LVD was higher in PC and PMC (P=0.001), and VEGF-C expression was increased in PC (P<0.0001). Despite higher LVD and increased expression of VEGF-A and VEGF-C in thyroid cancers, these markers were not related to poor prognosis in terms of tumour size, multifocality and/or presence of lymphatic or distant metastases. In conclusion, angiogenesis is reduced in thyroid proliferative lesions compared with NT tissue. However, VEGF-A expression is upregulated in thyroid cancers. Lymphangiogenesis and VEGF-C expression are increased in thyroid tumours prone to lymphatic metastases. This may be an important mechanism underlying the differences in metastatic behaviour between papillary and follicular thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954441     DOI: 10.1677/erc.1.01210

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  25 in total

1.  Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma.

Authors:  Wenjun Wang; Zhu-lin Yang; Jie-qiong Liu; Song Jiang; Xiong-ying Miao
Journal:  Tumour Biol       Date:  2011-11-12

2.  Axillary node metastasis from differentiated thyroid carcinoma with Hürthle and signet ring cell differentiation. A case of disseminated thyroid cancer with peculiar histologic findings.

Authors:  Maria Grazia Chiofalo; Nunzia Simona Losito; Franco Fulciniti; Sergio Venanzio Setola; Antonio Tommaselli; Ugo Marone; Maria Luisa Di Cecilia; Luciano Pezzullo
Journal:  BMC Cancer       Date:  2012-02-03       Impact factor: 4.430

3.  Lymphatic vessel density and VEGF-C expression are significantly different among benign and malignant thyroid lesions.

Authors:  Eduardo Anselmo Garcia; Kleber Simões; Alda Wakamatsu; Rodrigo Albergaria Ressio; Venâncio Avancini Ferreira Alves; Adhemar Longatto-Filho; Roberto Souza Camargo
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

Review 4.  Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer.

Authors:  A D Karatzanis; E Koudounarakis; I Papadakis; G Velegrakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-21       Impact factor: 2.503

5.  Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations.

Authors:  Marilena Celano; Marialuisa Sponziello; Giovanni Tallini; Valentina Maggisano; Rocco Bruno; Mariavittoria Dima; Enrico Di Oto; Adriano Redler; Cosimo Durante; Rosario Sacco; Sebastiano Filetti; Diego Russo
Journal:  Endocrine       Date:  2012-07-20       Impact factor: 3.633

Review 6.  Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review.

Authors:  Nickolay Fedchenko; Janin Reifenrath
Journal:  Diagn Pathol       Date:  2014-11-29       Impact factor: 2.644

7.  Intratumoural lymph vessel density is related to presence of lymph node metastases and separates encapsulated from infiltrative papillary thyroid carcinoma.

Authors:  C Eloy; J Santos; P Soares; M Sobrinho-Simões
Journal:  Virchows Arch       Date:  2011-11-12       Impact factor: 4.064

8.  Targeted therapies in thyroid cancer.

Authors:  Jaume Capdevila; Jose Perez-Garcia; Gabriel Obiols; Josep Tabernero
Journal:  Target Oncol       Date:  2009-11-11       Impact factor: 4.493

9.  Enhanced nestin expression and small blood vessels in human pituitary adenomas.

Authors:  María Inés Perez-Millan; Silvia Inés Berner; Guillermina María Luque; Cristian De Bonis; Gustavo Sevlever; Damasia Becu-Villalobos; Carolina Cristina
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

10.  Microvessel density and area in pituitary microadenomas.

Authors:  Ewa Jasek; Alicja Furgal-Borzych; Grzegorz J Lis; Jan A Litwin; Ewa Rzepecka-Wozniak; Franciszek Trela
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.